Mariachiara Dipasquale - Publications

Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 02, 2026

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Journal: Journal of clinical medicine

Published: November 23, 2025

Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives.

Journal: Cancers

Published: January 12, 2025

Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line.

Journal: Cancers

Published: November 03, 2024

Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.

Journal: Journal of clinical medicine

Published: May 09, 2024

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

Journal: Seminars in oncology

Published: May 03, 2023

Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.

Journal: Targeted oncology

Published: November 09, 2022

Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis.

Journal: Joint bone spine

Published: September 18, 2021

Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.

Journal: Immunotherapy

Published: June 30, 2021

Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.

Journal: Critical reviews in oncology/hematology

Published: January 17, 2021

Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature.

Journal: Future oncology (London, England)

Published: January 06, 2021

Role of circulating tumor DNA in the detection of sensitizing and resistance to epidermal growth factor receptor mutations in metastatic lung adenocarcinoma.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: June 12, 2020